Sophia GeneticsFRA:90B -4.55%73 EV-to-FCF is -9.06 as of Jul. 06, 2026. GuruFocus rates FRA:90B with a GF Score™ of 73/100 and a GF Value™ of €4.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 405 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 246913.33% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sophia Genetics's Enterprise Value is €391.53 Mil.
Sophia Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-43.23 Mil. Therefore, Sophia Genetics's EV-to-FCF for today is -9.06.
The historical rank and industry rank for Sophia Genetics's EV-to-FCF or its related term are showing as below:
FRA:90B'
s EV-to-FCF Range Over the Past 10 Years
Min: -23.19 Med: -3.27 Max: 1.01
Current: -8.88
During the past 8 years, the highest EV-to-FCF of Sophia Genetics was 1.01. The lowest was -23.19. And the median was -3.27.
FRA:90B's EV-to-FCF is ranked worse than 100% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 17.97
vs FRA:90B: -8.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sophia Genetics's PE Ratio (TTM) for today is calculated as:
Sophia Genetics's share price for today is €4.62.
Sophia Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sophia Genetics EV-to-FCF Related Terms
Sophia Genetics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's EV-to-FCF falls into.
Sophia Genetics's current Enterprise Value is €391.53 Mil.
Sophia Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-43.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (FRA:90B) has a EV-to-FCF of -9.06 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #999999 out of 405 companies in the Healthcare Providers & Services industry.
Is Sophia Genetics' EV-to-FCF too high?
Sophia Genetics' current EV-to-FCF is -9.06. Based on the distribution chart, Sophia Genetics ranks #999999 out of 405 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' EV-to-FCF compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #999999 out of 405 companies for EV-to-FCF. This places Sophia Genetics in the lower half of its industry. The industry median EV-to-FCF is 17.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.97, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current EV-to-FCF is -9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Fairly Valued. The stock's GF Value™ is €4.35, compared to a current price of €4.62 — trading 6.2% above its estimated fair value. The current EV-to-FCF is -9.06. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current EV-to-FCF is -9.06 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (FRA:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €4.62 is trading 6.2% above its estimated GF Value™ of €4.35.
GuruFocus considers Sophia Genetics to be Fairly Valued.
Key valuation signals for FRA:90B:
EV-to-FCF: -9.06
GF Value™: €4.35 vs. price of €4.62 (6.2% above fair value)
No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score
Get the complete analysis for FRA:90B
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:90B has been successfully added to your 
